Breaking News Instant updates and real-time market news.

XLRN

Acceleron

$33.95

1.52 (4.69%)

, CELG

Celgene

$133.68

0.85 (0.64%)

05:40
06/23/17
06/23
05:40
06/23/17
05:40

Acceleron says results from ongoing trials demonstrate increases in hemoglobin

Acceleron Pharma (XLRN) announced preliminary results from the ongoing Phase 2 studies of luspatercept in patients with lower-risk myelodysplastic syndromes, or MDS, at the 22nd Congress of the European Hematology Association in Madrid, Spain. Luspatercept is being developed to treat a range of hematologic diseases including MDS, beta-thalassemia, and myelofibrosis as part of a global collaboration between Acceleron and Celgene (CELG). "This Phase 2 update further supports our confidence that luspatercept could become a potential first-in-class treatment for lower-risk MDS patients. With some patients continuing on study for more than 26 months, we are very encouraged by both the durability of response and safety profile of luspatercept," said Habib Dable, President and CEO of Acceleron. "With Phase 3 trials across two indications ongoing and new studies planned, we and Celgene remain committed to exploring the full opportunity for luspatercept to transform patients' lives."

XLRN

Acceleron

$33.95

1.52 (4.69%)

CELG

Celgene

$133.68

0.85 (0.64%)

  • 23

    Jun

XLRN Acceleron
$33.95

1.52 (4.69%)

06/13/17
OPCO
06/13/17
DOWNGRADE
OPCO
Perform
Acceleron downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Leah Rush Cann downgraded Acceleron Pharma to Perform after dalantercept plus axitinib failed to meet its primary endpoint in advanced renal cell carcinoma. The analyst lowered her 2021 revenue estimate by nearly 68% to $120.6M to reflect the discontinuation of dalantercept.
06/13/17
FBCO
06/13/17
NO CHANGE
Target $35
FBCO
Outperform
Acceleron price target lowered to $35 from $46 at Credit Suisse
Credit Suisse analyst Alethia Young removed dalantercept from her valuation of Acceleron after the company announced that they will discontinue development of the drug following the failure of their RCC study. Removing the drug from her model led Young to lower her price target on the stock to $35 from $46, though she keeps an Outperform rating, citing the long-term potential seen for luspatercept.
06/13/17
JMPS
06/13/17
NO CHANGE
JMPS
Acceleron should be bought on any weakness, says JMP Securities
After Acceleron's dalantercept missed its primary endpoint in advanced renal cell carcinoma in a trial, JMP Securities analyst Michael King says that the drop in the stock is overdone. He cut his price target on the shares to $34 from $39 but recommends buying the shares today on any weakness.
06/13/17
06/13/17
NO CHANGE
Target $63

Outperform
FBR keeps $61 target on Acceleron after dalantercept failure
FBR Capital analyst Ed White says that while the dalantercept failed Phase II study is "disappointing," his focus remains on luspatercept, which is being studied in beta-thalassemia and myelodysplastic syndrome. Celgene (CELG) estimates peak sales potential of over $2B for luspatercept, which could translate into more than $400M in revenue for Acceleron Pharma (XLRN), White tells investors in a research note. He thinks luspatercept could be brought to market by 2019. White's price target for Acceleron remains $63 as he had only a 15% probability of approval and a low revenue estimate for dalantercept. The analyst reiterates an Outperform rating on the shares.
CELG Celgene
$133.68

0.85 (0.64%)

06/16/17
LEER
06/16/17
UPGRADE
Target $150
LEER
Outperform
Celgene upgraded to Outperform from Market Perform at Leerink
Leerink analyst Geoffrey Porges upgraded Celgene to Outperform and raised his price target for the shares to $150 from $146.
06/16/17
LEER
06/16/17
UPGRADE
Target $150
LEER
Outperform
Leerink upgrades Celgene to Outperform on 'discounted valuation'
Leerink analyst Geoffrey Porges upgraded Celgene to Outperform from Market Perform and raised his price target for the shares to $150 from $146. The biopharmaceutical company closed yesterday down 43c to $120.61. The analyst, who points out his revenue estimates for 2017-2019 are above the consensus, views Celgene's valuation as "discounted." The analyst expects the company's operating results to rebound in Q2 and stock's multiple to recover in Q3 "towards a more growth-appropriate range." He also anticipates "significant upward revisions" to consensus expectations in Q3.
06/16/17
06/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Teva (TEVA) upgraded to Neutral from Underperform at Mizuho with analyst Irina Koffler citing reduced near-term risk of a Mylan's (MYL) generic Copaxone approval, potential asset sale announcements, and encouraging May subscription trends. 2. Brookfield Infrastructure (BIP) upgraded to Outperform from Neutral at Credit Suisse with analyst Andrew Kuske saying the potential inclusion of Brookfield Infrastructure into the S&P Index is likely to have a "meaningful impact" on demand around the third quarter index revision. 3. Celgene (CELG) upgraded to Outperform from Market Perform at Leerink with analyst Geoffrey Porges saying he views Celgene's valuation as "discounted." 4. Regency Centers (REG) upgraded to Buy from Hold at Jefferies with analyst George Hoglund saying he believes the recent pullback in the shares creates an attractive entry point. 5. Nanometrics (NANO) upgraded to Buy from Hold at Stifel with analyst Patrick Ho citing valuation, along with his belief that wafer lab equipment spending will be strong next year and that the "elevated spending" level may be sustainable. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/22/17
LEER
06/22/17
NO CHANGE
LEER
Leerink sees reasons for biotech rally to continue
Leerink analyst Geoffrey Porges attributes the recent strength in the biotech sector to a lessening of the perceived fears of pricing regulations and a favorable tone from the FDA. However, he believes the sector could advance at least 15% more, as he foresees more positive operating results and still expects more industry consolidation. Among large cap biotech names, Porges maintains Outperform ratings on Regeneron (REGN), Celgene (CELG), Vertex (VRTX) and Alexion(ALXN) and keeps Market Perform ratings on AbbVie (ABBV), Amgen (AMGN), Gilead (GILD) and Biogen (BIIB).

TODAY'S FREE FLY STORIES

SNSS

Sunesis

$2.87

0.01 (0.35%)

, ABBV

AbbVie

$93.60

-0.01 (-0.01%)

08:58
11/21/17
11/21
08:58
11/21/17
08:58
Initiation
Sunesis, AbbVie initiated  »

Oppenheimer says Sunesis…

SNSS

Sunesis

$2.87

0.01 (0.35%)

ABBV

AbbVie

$93.60

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSW

DSW

$22.53

0.38 (1.72%)

08:57
11/21/17
11/21
08:57
11/21/17
08:57
Technical Analysis
Technical View: DSW down sharply after earnings, outlook, miss consensus »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

A

Agilent

$69.96

1.17 (1.70%)

08:57
11/21/17
11/21
08:57
11/21/17
08:57
Recommendations
Agilent analyst commentary  »

Agilent price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

GE

General Electric

$17.98

-0.23 (-1.26%)

, BAC

Bank of America

$26.74

0.12 (0.45%)

08:55
11/21/17
11/21
08:55
11/21/17
08:55
Options
Notable open interest changes for November 21st »

Monday's total…

GE

General Electric

$17.98

-0.23 (-1.26%)

BAC

Bank of America

$26.74

0.12 (0.45%)

BABA

Alibaba

$188.00

2.87 (1.55%)

AAPL

Apple

$169.98

-0.17 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGY

Stone Energy

$35.49

1.15 (3.35%)

08:55
11/21/17
11/21
08:55
11/21/17
08:55
Hot Stocks
Breaking Hot Stocks news story on Stone Energy »

Stone Energy trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NETS

Netshoes

08:53
11/21/17
11/21
08:53
11/21/17
08:53
Recommendations
Netshoes analyst commentary  »

Netshoes valuation overly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$53.50

0.5 (0.94%)

08:51
11/21/17
11/21
08:51
11/21/17
08:51
Recommendations
Cubic analyst commentary  »

Cubic price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AXGN

AxoGen

$24.30

0.7 (2.97%)

08:51
11/21/17
11/21
08:51
11/21/17
08:51
Recommendations
AxoGen analyst commentary  »

AxoGen price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

CPB

Campbell Soup

$49.93

0.21 (0.42%)

08:48
11/21/17
11/21
08:48
11/21/17
08:48
Hot Stocks
Campbell continues to expect Campbell Fresh to return to profitability this year »

Says back to normal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

GE

General Electric

$17.98

-0.23 (-1.26%)

08:48
11/21/17
11/21
08:48
11/21/17
08:48
Recommendations
General Electric analyst commentary  »

Deutsche Bank cuts target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EV

Eaton Vance

$52.27

0.48 (0.93%)

08:48
11/21/17
11/21
08:48
11/21/17
08:48
Hot Stocks
Eaton Vance reports AUM $382.4B for FY17 »

This represents an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

EV

Eaton Vance

$52.27

0.48 (0.93%)

08:46
11/21/17
11/21
08:46
11/21/17
08:46
Earnings
Eaton Vance reports Q4 adjusted EPS 70c, consensus 71c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MBI

MBIA

$8.95

-0.06 (-0.67%)

, GME

GameStop

$16.44

0.13 (0.80%)

08:45
11/21/17
11/21
08:45
11/21/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

MBI

MBIA

$8.95

-0.06 (-0.67%)

GME

GameStop

$16.44

0.13 (0.80%)

AAOI

Applied Optoelectronics

$43.48

-1.56 (-3.46%)

XLV

Health Care Select Sector SPDR

$80.90

-0.34 (-0.42%)

NUGT

Direxion Gold Miners Bull

$28.92

-0.88 (-2.95%)

OSTK

Overstock.com

$56.65

4.25 (8.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 28

    Nov

  • 29

    Nov

08:45
11/21/17
11/21
08:45
11/21/17
08:45
General news
U.S. October Chicago Fed National Activity index rose 0.29 points to 0.65 »

U.S. October Chicago Fed…

SSY

SunLink Health Systems

08:45
11/21/17
11/21
08:45
11/21/17
08:45
Hot Stocks
Breaking Hot Stocks news story on SunLink Health Systems »

Sunlink Health Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$81.46

1.24 (1.55%)

08:44
11/21/17
11/21
08:44
11/21/17
08:44
Recommendations
Lowe's analyst commentary  »

Lowe's quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

08:43
11/21/17
11/21
08:43
11/21/17
08:43
Recommendations
Palo Alto Networks analyst commentary  »

Palo Alto Networks price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

CPB

Campbell Soup

$49.93

0.21 (0.42%)

08:43
11/21/17
11/21
08:43
11/21/17
08:43
Hot Stocks
Campbell Soup says expects to complete Pacific Foods acquisition by year-end »

Says saw lower seasonal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SHOP

Shopify

$108.56

3.67 (3.50%)

, FB

Facebook

$178.74

-0.26 (-0.15%)

08:43
11/21/17
11/21
08:43
11/21/17
08:43
Recommendations
Shopify, Facebook analyst commentary  »

Shopify price target…

SHOP

Shopify

$108.56

3.67 (3.50%)

FB

Facebook

$178.74

-0.26 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,126.31

-3.57 (-0.32%)

, RAD

Rite Aid

$1.56

-0.03 (-1.89%)

08:41
11/21/17
11/21
08:41
11/21/17
08:41
Recommendations
Amazon.com, Rite Aid analyst commentary  »

Amazon pharmacy…

AMZN

Amazon.com

$1,126.31

-3.57 (-0.32%)

RAD

Rite Aid

$1.56

-0.03 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

SGY

Stone Energy

$35.49

1.15 (3.35%)

08:41
11/21/17
11/21
08:41
11/21/17
08:41
Hot Stocks
Stone Energy, Talos to become wholly-owned subsidiaries of new holding company »

Under the terms of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:40
11/21/17
11/21
08:40
11/21/17
08:40
General news
Breaking General news story  »

Week of 11/18 Redbook to…

VKTX

Viking Therapeutics

$2.77

-0.02 (-0.72%)

08:39
11/21/17
11/21
08:39
11/21/17
08:39
Initiation
Viking Therapeutics initiated  »

Viking Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QD

Qudian

$20.08

-1.12 (-5.28%)

08:39
11/21/17
11/21
08:39
11/21/17
08:39
Periodicals
Netease reports China stops approving new online micro lenders, Bloomberg says »

China's Internet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGY

Stone Energy

$35.49

1.15 (3.35%)

08:39
11/21/17
11/21
08:39
11/21/17
08:39
Hot Stocks
Stone Energy, Talos Energy combination to have ADP of about 47 Mboe »

The combination will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.